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ttp://dx.doi.org/10.1016/j.ajpath.2016.01.002Duchenne muscular dystrophy is a lethal X-linked muscle disorder. We have already reported that
osteopontin (OPN), an inﬂammatory cytokine and myogenic factor, is expressed in the early dystrophic
phase in canine X-linked muscular dystrophy in Japan, a dystrophic dog model. To further explore the
possibility of OPN as a new biomarker for disease activity in Duchenne muscular dystrophy, we moni-
tored serum OPN levels in dystrophic and wild-type dogs at different ages and compared the levels to
other serum markers, such as serum creatine kinase, matrix metalloproteinase-9, and tissue inhibitor of
metalloproteinase-1. Serum OPN levels in the dystrophic dogs were signiﬁcantly elevated compared with
those in wild-type dogs before and 1 hour after a cesarean section birth and at the age of 3 months. The
serum OPN level was signiﬁcantly correlated with the phenotypic severity of dystrophic dogs at the
period corresponding to the onset of muscle weakness, whereas other serum markers including creatine
kinase were not. Immunohistologically, OPN was up-regulated in inﬁltrating macrophages and devel-
opmental myosin heavy chainepositive regenerating muscle ﬁbers in the dystrophic dogs, whereas
serum OPN was highly elevated. OPN expression was also observed during the synergic muscle regen-
eration process induced by cardiotoxin injection. In conclusion, OPN is a promising biomarker for
muscle regeneration in dystrophic dogs and can be applicable to boys with Duchenne muscular
dystrophy. (Am J Pathol 2016, 186: 1302e1312; http://dx.doi.org/10.1016/j.ajpath.2016.01.002)Supported by Neurological and Psychiatric Disorders of the National
Center of Neurology and Psychiatry intramural research grants 22-5 and 25-
5 (S.T.) and Japan Society for the Promotion of Science Grants-in-Aid for
Scientiﬁc Research grant 24591284 (E.K.).
Disclosures: None declared.Duchenne muscular dystrophy (DMD) is an X-linked dis-
order of muscle characterized by primary muscle atrophy.1
Its prevalence in the population is estimated to be 1 in
3500 male newborns.2 A DMD gene mutation results in the
absence of dystrophin, a structural protein in muscle ﬁbers,
leading to fragility of muscle ﬁbers to contractive force.3
Histologic features of DMD are muscle ﬁber degeneration
with secondary cellular inﬂammation, ineffective muscle
ﬁber regeneration, and eventually ﬁbrosis and adiposis.
Hence, patients with DMD have muscle weakness, leading
to loss of ambulation and early death from respiratory or
cardiac failure.
Clinical biomarkers are necessary for the diagnosis of
the disease, classiﬁcation of the severity, and evaluation ofstigative Pathology. Published by Elsevier Inc
Y-NC-ND license (http://creativecommons.orgtherapeutic effects. Serum creatine kinase (CK) is a pri-
mary biomarker for the sensitive diagnosis of DMD,
reﬂecting muscle damage.4 However, serum CK is not
sufﬁcient for the evaluation of therapeutic effects because
its levels decrease with the progression of dystrophic dis-
ease corresponding to skeletal muscle waste. Osteopontin
(OPN) is a potential new candidate for development of a
method for evaluation of dystrophic conditions. OPN is a.
/licenses/by-nc-nd/4.0).
Serum Osteopontin in Dystrophic Dogsphosphorylated glycoprotein that is synthesized in a vari-
ety of tissues and cells, and participates in inﬂammation,
tissue remodeling, and tumorigenesis.5,6 The secreted form
of OPN, both as a soluble molecule with cytokine functions
and as an immobilized matricellular protein, can interact
with CD44 and a variety of integrins to activate intracel-
lular signaling pathways and mediate cell-cell and cell-
matrix interactions.5,7 The effects of binding of OPN to
target cells, including promotion of attachment, prolifera-
tion, migration, and chemotaxis of cells, are modulated
through cleavage by thrombin and matrix metal-
loproteinase (MMP)-3, -7, and -12.8,9 In injured or
dystrophic muscles, OPN is reportedly expressed in im-
mune cells, myoblasts, and damaged or regenerating
muscle ﬁbers, indicating its functional involvement in
cellular inﬂammation, muscle regeneration, and
ﬁbrosis.10e16 Serum OPN level elevation is also observed
in X-linked muscular dystrophy (mdx) mice.13 OPN may
inﬂuence the severity of disease in patients with DMD
because single-nucleotide polymorphisms in human SPP1
(OPN ) correlate with the results of clinical trials.17e19 In
our previous study using a dystrophin-deﬁcient dog model,
canine X-linked muscular dystrophy in Japan (CXMDJ),
we found that OPN is implicated in dystrophic diaphragms
at birth before initial respiration, suggesting the partici-
pation of OPN in a dystrophic muscle environment even at
an early phase.20
In a recent study of other serum biomarkers for which the
biological function may be related to that of OPN, MMP-9
and its endogenous inhibitor, tissue inhibitor of metal-
loproteinase (TIMP)-1, are strongly suggested to be DMD
biomarkers.21 MMP-9 is a proteolytic enzyme that degrades
extracellular matrix components and is prominently
involved in the inﬂammatory process during muscle
degeneration.22e24 TIMP-1 possesses biological properties
independent of MMP inhibitory activity, including stimu-
lation of cell proliferation and antiapoptosis.25,26 Elevation
of serum MMP-9 and TIMP-1 levels is associated with
dystrophic disease, and MMP-9 levels correlate with clinical
nonambulation of patients with DMD.21
We hypothesized that OPN is uniquely expressed at
the early dystrophic phase, and could therefore be a new
biomarker of DMD. However, what the serum OPN
level indicates in dystrophic disease is still unclear
because its elevation is not constantly observed during
disease progression.13,21 In the present study, we
analyzed serum OPN levels in CXMDJ dystrophic dogs
and wild-type (WT) controls at birth and during growth
periods and compared them with levels of serum CK,
MMP-9, and TIMP-1. We report here for the ﬁrst time
that the serum OPN level in dystrophic dogs was
signiﬁcantly higher than in WT at birth and in the active
muscle regeneration phase. OPN was expressed in inﬁl-
trating immune cells and regenerating muscle ﬁbers in
dystrophic muscles, suggesting an association with
elevated serum OPN levels.The American Journal of Pathology - ajp.amjpathol.orgMaterials and Methods
Animals
A CXMDJ dog colony was established by insemination of
beagles with the sperm of golden retriever muscular dystrophy
(GRMD) dogs.27 CXMDJ dystrophic dogs lack dystrophin in
the muscle tissue and have dystrophic phenotypes, as observed
inGRMDand in humanDMD.28All the animals were cared for
and treated in accordance with the guidelines provided by the
Ethics Committee for the Treatment of Laboratory Middle-
sized Animals of the National Institute of Neuroscience.
Forty-nine CXMDJ dystrophic and 40 WT littermates in the
second to seventh generations from the ﬁrst artiﬁcial insemi-
nation were used in this study. All the serum and muscle
samples in this study were routinely taken from the dystrophic
and WT dogs raised between September 2002 and September
2014 except the ones used for other interventional studies.
Anesthesia in the dystrophic and WT dogs was induced by
intravenous injection of 20 mg/kg of thiopental sodium
(Ravonal, Mitsubishi Tanabe Pharma, Osaka, Japan) and
maintained by inhalation of isoﬂurane (Isoﬂu, DS Pharma
Animal Health Co., Osaka, Japan). Euthanization was con-
ducted by exsanguination under the anesthetic condition.
Serum Collection and Serum Chemistry
Blood samples were collected from each dog at birth, at the age
of 3 and 6 weeks, at 2, 3, 6, and 9 months, and at 1 and 2 years.
Umbilical cord blood was obtained after fetuses were expelled
with a cesarean section, and blood was withdrawn from all the
neonates 1 hour after the initial respiration.20 Each blood sample
was treated and assayed for serum CK activity using an auto-
mated colorimetric analyzer (FDC3500, Fuji Film Medical Co.
Ltd., Tokyo, Japan), as previously reported.29
Enzyme-Linked Immunosorbent Assay Analysis
Serum OPN, MMP-9, and TIMP-1 levels were determined
using an enzyme-linked immunosorbent assay (ELISA) kit
(USCN Life Science Inc., Wuhan, China) for Canis familiaris
OPN (E90899Ca), MMP-9 (E90553Ca), and TIMP-1
(E90552Ca). Sample application was performed in duplicate
according to the manufacturer’s instructions. Optical density
values of standards and samples were spectrophotometrically
measured at a wavelength of 450 nm using a microplate reader
(Appliskan, Thermo Fisher Scientiﬁc, Waltham, MA). When
the values were below the detection limit, they were assigned a
value of zero.
Clinical Manifestations
Clinical evaluation of dystrophic dogs as described in our
previous reports28e30 was performed with revision of some of
the items. Brieﬂy, we evaluated gait and mobility disturbances,
limb and temporal muscle atrophy, drooling, macroglossia,1303
Figure 1 Patterns of elevation of serum
osteopontin (OPN), creatine kinase (CK), matrix
metalloproteinase (MMP)-9, and tissue inhibitor
of metalloproteinase (TIMP)-1 in wild-type (WT)
and dystrophic dogs. A: Paired serum OPN and CK
levels in WT and dystrophic dogs before and after
birth. Cord and 1 hour indicate serum obtained
before and after birth, respectively. Bars indicate
the mean value. B: Serum OPN, CK, MMP-9, and
TIMP-1 levels at the different ages. The data are
the means  SEM. n Z 16 for WT and dystrophic
dogs in serum OPN (A); n Z 13 for WT dogs in
serum CK (A); nZ 12 for dystrophic dogs in serum
CK (A). *P < 0.05 and **P < 0.01 versus WT using
t-test; yyP < 0.01 versus cord values in WT using
paired t-test in A. zP < 0.05 versus WT using t-test
with the Holm multiple test; xP < 0.05 and xxP <
0.01 compared between values of the cord and
each age point in WT or dystrophic dogs using
Dunnett’s test in B.
Kuraoka et aldysphagia, and abnormal sitting posture as clinical signs. The
severity of each signwas classiﬁed into scores of 1 to 5 (grade 1,
none; grade 5, severe) according to a grading scale for CXMDJ
(Supplemental Table S1).We used the grading records between
October 2007 and May 2013.
Histopathology and Immunohistochemistry
The diaphragm and tibialis cranialis (TC) muscle tissues were
sampled by autopsy, as previously described.20,29,31 Brieﬂy,
muscle tissueswere snap-frozen in cooled isopentane and stored
at 80C before use. Cryostat sections (8 mm) were serially
prepared and routinely stained with hematoxylin and eosin.
Immunostaining was performed on serial sections, as previ-
ously described.20 Brieﬂy, all sections were ﬁxed in cooled
acetone and blocked with Block Ace (Dainippon SumitomoTable 1 Correlation between Serum Biomarker Levels and Total Clinic
Variable Osteopontin
n 11
Pearson correlation coefﬁcient 0.672*
Data with missing values were removed from the analysis.
*P < 0.05.
CK, creatine kinase; MMP-9, matrix metalloproteinase-9; TIMP-1, tissue inhibit
1304Pharma Co., Ltd., Osaka, Japan). Subsequently, the specimens
were labeled with primary rabbit polyclonal antibodies to OPN
(dilution, 1:100) (RB-9097, Thermo Fisher Scientiﬁc), MMP-9
(dilution, 1:1000) (ab38898, Abcam, Cambridge, UK), or
TIMP-1 (dilution, 1:200) (AB770, EMD Millipore Corp.,
Temecula, CA) and with mouse monoclonal antibodies to
developmental myosin heavy chain (dMyHC) (dilution, 1:40)
(NCL-MHCd, Leica Biosystems, Newcastle, UK), CD11b
(dilution, 1:50) (MCA1777S, AbD Serotec, Kidlington,
Oxford, UK), CD3 (dilution, 1:50) (MCA1774GA, AbD
Serotec), CD18 (dilution, 1:10) (MCA1780, AbD Serotec),
CD68 (dilution, 1:100) (MCA1815T, AbD Serotec), or CD206
(dilution, 1:50) (MCA2519GA, AbD Serotec). Secondary an-
tibodies used were ﬂuorescein-conjugated goat anti-rabbit or
anti-mouse IgG (Alexa Fluor 488 or 568, respectively; dilution,
1:1000; Life Technologies, Carlsbad, CA). All sections wereal Scores in Dystrophic Dogs at the Age of 2 Months
CK MMP-9 TIMP-1
11 10 9
0.221 0.132 0.485
or of metalloproteinase-1.
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Figure 2 Osteopontin (OPN) expression in
inﬁltrating macrophages of dystrophic muscles at
birth. Serial sections of wild-type (WT) and
dystrophic diaphragm and tibialis cranialis (TC)
muscles before (A) and after (B) initial respiration
are stained with hematoxylin and eosin (H&E) or
immunostained for OPN (green) and CD11b (red).
Merged immunostained images co-stained with
DAPI (blue; nucleus) are also shown. Scale bar Z
40 mm.
Serum Osteopontin in Dystrophic Dogsmounted with ﬂuorescent mounting medium containing DAPI
(Vectashield, Vector Laboratories Inc., Burlingame, CA).
Images were captured with a ﬂuorescence microscope BZ-
9000 (Keyence, Osaka, Japan) under identical conditions.
Muscle Fiber Counting
All ﬂuorescent images were analyzed with a computer-aided
image analysis system (BZ-II Analyzer 1.41, Keyence). Muscle
ﬁber counting was performed to compare the population of
OPN- and/or dMyHC-positive muscle ﬁbers. In the dystrophic
diaphragm and TC muscle tissues, OPN- and/or dMyHC-
positive muscle ﬁbers were counted after removal of weakly
positive ﬁbers and were compared at the age of 2 to 4 weeks, 3
to 5months, and 1 and 2 to 4 years. In each section, four randomThe American Journal of Pathology - ajp.amjpathol.orgﬁelds (in original magniﬁcation 20) were selected per spec-
imen. OPN- and dMyHC-positive or -negative ﬁbers in these
ﬁelds were manually captured, and the number was measured.
The total number of muscle ﬁbers was measured with bright
images in which we were able to capture ﬁber outlines. The
percentage of positive muscle ﬁbers was calculated as follows:
Total Number of Positive Muscle Fibers/Total Number of
Muscle Fibers  100 (Total Numbers Were Summed From
Four Fields).
Cardiotoxin Injection
Nine WT dogs at the age of 3 to 4.5 months were anesthetized
and injected with cardiotoxin (a venom from Naja mossambica
mossambica, 50 mmol/L, 0.21 mL/kg) (C9759, Sigma-Aldrich,1305
Figure 3 Osteopontin (OPN) expression in
dystrophic muscles at the age of 3 weeks, 3.5
months, and 1 and 2 years. Serial sections of
diaphragm and tibialis cranialis (TC) muscles of
wild-type (WT) and dystrophic dogs are stained
with hematoxylin and eosin (H&E) and immuno-
stained for OPN (green). Muscles from dogs at the
age of 3 weeks, 3.5 months, and 1 and 2 years
were stained. Scale bar Z 100 mm.
Kuraoka et alSt. Louis, MO) into the bilateral TC muscles to induce muscle
injury and subsequent regeneration.10 For analgesia treatment,
0.02 mg/kg of buprenorphine hydrochloride (Lepetan, Otsuka
Pharmaceutical, Tokyo, Japan) was injected i.m. before the
dogs awoke from general anesthesia. Blood samples were
collected before injection and 1, 3, 5, and 7 days after injection.
Three dogs were euthanized and the bilateral TC muscles
removed at 3, 5, and 7 days after injection, respectively. Serum
CK and OPN measurement and immunohistological analysis
were performed as described above.
Statistical Analysis
For analysis of serum before and after birth, biomarker
levels were compared with a paired t-test, and those1306between WT and dystrophic dogs were compared with an
unpaired t-test. For serum level analyses at different ages,
the Holm multiple test32,33 was applied in multiple com-
parisons between WT and dystrophic levels at all age
points. In addition, serum biomarker levels at each age
point were compared with the prebirth level with Dunnett’s
test. For analysis of cardiotoxin injection, serum biomarker
levels on each postinjection day were compared with the
preinjection level in the same animals using a paired t-test,
and the Holm multiple test was used at all postinjection
days. For analysis of the percentage of immunopositive
muscle ﬁbers, the percentages of OPN- and/or dMyHC-
positive muscle ﬁbers in each age range were calculated,
and the median values were compared to those at the age of
2 to 4 years using the Mann-Whitney U test withajp.amjpathol.org - The American Journal of Pathology
Figure 4 Osteopontin (OPN) expression in regenerating muscle ﬁbers of
dystrophic muscles. Sections of dystrophic diaphragm (A) and tibialis
cranialis (TC) (B) muscles are immunostained for OPN (green) and devel-
opmental myosin heavy chain (dMyHC, red) at the age of 3 weeks, 3.5
months, and 1 and 2 years. Merged images co-stained with DAPI (blue;
nucleus) are shown on the right. Higher magniﬁcation images are shown in
Supplemental Figure S2. Scale bar Z 100 mm.
Serum Osteopontin in Dystrophic DogsBonferroni correction. Pearson’s correlation was used for
correlation studies. The statistical signiﬁcance level was
set at 5%. In the Holm multiple test,32 the tests were or-
dered from those with the smallest P value to the largest P
value. The test with the lowest probability was then tested
ﬁrst, followed by Bonferroni correction for all tests. The
second test was tested with Bonferroni correction
involving one less test and so on for the remaining tests. All
data are given as the means  SEM, unless otherwise
noted. All calculations were performed with StatView-J
software version 5.0 (SAS Institute Inc., Cary, NC).
Results
Analyses of Serum OPN and CK Levels in Dystrophic
Dogs at Birth
Serum OPN and CK levels in CXMDJ dystrophic and
WT littermates were analyzed using cord blood samples
before and 1 hour after birth in a parametric manner
(Figure 1A). Serum OPN levels in dystrophic dogs were
signiﬁcantly higher both before and after birth than those
of WT dogs. Serum OPN levels were not signiﬁcantly
different between before and after birth in either WT or
dystrophic dogs. On the other hand, serum CK levels in
dystrophic dogs were signiﬁcantly higher before and
after birth than those of WT, and the postbirth level was
drastically increased compared with before birth.
Analyses of Serum Biomarker Levels in Dystrophic Dogs
during Growth Periods
Serum OPN, CK, MMP-9, and TIMP-1 levels were
examined at different ages during growth periods in a
nonparametric manner (Figure 1B). Serum OPN levels in
dystrophic dogs were signiﬁcantly higher than those in WT
before and 1 hour after birth and at the age of 3 months.
The serum OPN level at the age of 3 weeks remained
higher but was not statistically signiﬁcant compared with
that of WT.
Serum CK levels in dystrophic dogs were signiﬁcantly
higher than those in WT at all age points (Figure 1B). The
serum CK level in dystrophic dogs transiently decreased at
the age of 3 weeks and then progressively increased again
until the age of 3 months.
Serum MMP-9 levels in dystrophic dogs were signiﬁ-
cantly higher at 1 hour after birth and the age of 3 months
than those in WT (Figure 1B). The serum MMP-9 level
was signiﬁcantly increased at 1 hour after birth but was
then decreased at the age of 3 weeks compared with the
prebirth value. Serum TIMP-1 levels in dystrophic dogs
were not signiﬁcantly different compared with those in
WT dogs at any of the age points (Figure 1B). The TIMP-
1 levels were slightly increased before and 1 hour after
birth and at the age of 3 weeks compared with those of
WT dogs.The American Journal of Pathology - ajp.amjpathol.orgAnalyses of Serum Biomarker Levels and Phenotypic
Severity in Dystrophic Dogs
We analyzed whether serum biomarkers, including OPN,
were correlated with phenotypic severity in dystrophic dogs.
For classiﬁcation of phenotypic variation, clinical manifes-
tations were investigated in dystrophic dogs at the age of 2
months, when they had onset of clinical signs.28 We found a
signiﬁcant correlation between the total grading score and
the serum OPN level, whereas no correlation was found
between the score and other markers, including serum CK
(Table 1).1307
Figure 5 Osteopontin (OPN) expression during
muscle regeneration after cardiotoxin-induced
injury. A: Serial sections of tibialis cranialis (TC)
muscles injured by cardiotoxin are stained with
hematoxylin and eosin (H&E) and immunostained
for OPN (green) and developmental myosin heavy
chain (dMyHC; red). Muscles from dogs at 3, 5, and
7 days after cardiotoxin injection. Merged images
co-stained with DAPI (blue; nucleus) are shown on
the right. B: High-magniﬁcation images of OPN
expression are shown after immunostaining for CD11b
at 3 days after injection or for dMyHC at 7 days after
injection. Merged DAPI (blue; nucleus)estained im-
ages are shown on the right. C: Serum OPN and cre-
atine kinase (CK) levels in wild-type dogs before and
after cardiotoxin injection. Each corrected pre-
injection and postinjection value of the same dogs
was calculated by dividing by the preinjection value.
Data are expressed as means SEM. nZ 9 for before
and after 1 and 3 days; nZ 6 for 5 days; nZ 3 for 7
days. *P < 0.05 versus preinjection value using a
paired t-test with the Holm multiple test. Scale bars:
100 mm (A); 20 mm (B).
Kuraoka et alOPN Expression in the Diaphragm and Limb Muscle at
Birth
We next performed immunostaining to observe OPN expres-
sion in WT and dystrophic muscle tissues around birth
(Figure 2) because the serum OPN levels in dystrophic dogs
revealed a distinct elevation pattern compared with serum CK.
Histologic analysis of WT muscles revealed no impairment in
muscle ﬁbers at birth and after initial respiration. In the
dystrophic diaphragms, we found a sporadic appearance of
opaque muscle ﬁbers before respiration (Figure 2A), whereas
massive degenerative ﬁbers were noted after respiration
(Figure 2B), as previously reported.20 OPN expression was
observed in inﬁltrating mononuclear cells, which were mostly
CD11b-positive immune cells, including macrophages
(Figure 2, A and B). Diffuse positive OPN staining was also
observed in some interstitial cells and in small muscle ﬁbers in
WT and dystrophic muscles.
Histologic examination of TC muscles of dystrophic dogs
revealed some opaque ﬁbers both before and after respiration
(Figure 2, A and B). In these dystrophic TC muscles, OPN1308was also expressed in CD11b-positive immune cells and in
small-sized muscle ﬁbers.
Diaphragmatic and Limb Muscle OPN Expression at
Different Ages
We then examined the pathologic process in dystrophic
muscles at different ages (Figure 3). No pathologic ﬁnd-
ings were observed in any of the WT muscles, and OPN
was only detected in some interstitial cells. In the dystro-
phic diaphragms, degenerative muscle ﬁbers accompa-
nying inﬁltration of mononuclear cells were often observed
at 3 weeks, 3.5 months, and 1 year of age. OPN was
expressed in inﬁltrating CD11b- and CD18-positive mac-
rophages or granulocytes but not CD3-positive T lym-
phocytes (Supplemental Figure S1). OPN-positive cells
were partly co-localized with CD68-positive M1 and
CD206-positive M2 macrophages. OPN was intensely
stained in a subset of muscle ﬁbers (Figure 3), suggesting
regenerating muscle ﬁbers. These OPN-positive ﬁbers
were frequently co-stained with dMyHC, an immature andajp.amjpathol.org - The American Journal of Pathology
Figure 6 Expression of osteopontin (OPN),
matrix metalloproteinase (MMP)-9, and tissue in-
hibitor of metalloproteinase (TIMP)-1 in dystro-
phic muscle. Serial sections of dystrophic tibialis
cranialis (TC) muscle at the age of 3.5 months are
stained with hematoxylin and eosin (H&E) or
immunostained for OPN, MMP-9, or TIMP-1 (green)
and co-stained for developmental myosin heavy
chain (dMyHC) or CD11b (red). Merged images that
were co-stained with DAPI (blue; nucleus) are
shown on the right. Asterisks indicate serial sec-
tions of the same muscle ﬁbers. Scale bar Z 100
mm.
Serum Osteopontin in Dystrophic Dogsregenerating muscle ﬁber marker (Figure 4A). In these ﬁbers,
OPN was strongly expressed in the cytoplasm (Supplemental
Figure S2). The histopathologic examination at the age of 2
years revealed ﬁbrosis (Figure 3), and OPN was only faintly
expressed in dMyHC-positive muscle ﬁbers (Figure 3 and
Figure 4A). In the dystrophic TC muscles, OPN was also
expressed in inﬁltrating mononuclear cells and a subset of
muscle ﬁbers (Figure 3). OPN-positive ﬁbers were co-stained
with dMyHC, as observed in the dystrophic diaphragm
(Figure 4B).
To examine the proportion of OPN-positive immature
and regenerating muscle ﬁbers, we analyzed the percentage
of OPN- and/or dMyHC-positive muscle ﬁbers at different
ages (Supplemental Figure S3). The percentages at each age
range were not signiﬁcantly different compared with that at
the age of 2 to 4 years because of the small sample size. In
the dystrophic diaphragm, the percentage of OPN and
dMyHC double-positive ﬁbers tended to be high at the age
of 2 to 4 weeks, 3 to 5 months, and 1 year compared with
that at the age of 2 to 4 years, whereas in the dystrophic TCThe American Journal of Pathology - ajp.amjpathol.orgmuscle, the value tended to be highest at the age of 3 to 5
months.
OPN Expression after Cardiotoxin Injection
We analyzed OPN expression during muscle injury induced by
cardiotoxin injection and subsequent regeneration in WT dogs
(Figure 5). In the injured TC muscle tissues, mononuclear cells
notably inﬁltrated in necrotic and edematous areas at 3 days after
injection. Regenerating muscle ﬁbers expressing dMyHC were
increased at 5 and 7 days after injection (Figure 5A). Similar
histologic features were observed in three WT dogs euthanized
at each postinjection day. OPN was markedly expressed in
CD11b-positive mononuclear cells and dMyHC-positive
regenerating muscle ﬁbers (Figure 5, A and B), indicating an
association with muscle regeneration, as observed in dystrophic
dogs. During muscle regeneration, serum OPN tended to in-
crease, but no signiﬁcant differences were seen at 3, 5, or 7 days
after injection (Figure 5C). SerumCKelevationwas observed at
1day after injection,when substantialmuscle injurywaspresent.1309
Kuraoka et alComparison of Tissue MMP-9 and TIMP-1 Expression
with OPN Expression
Different patterns of elevation were seen between serum
MMP-9 and TIMP-1 levels in dystrophic dogs compared with
serum OPN and CK. Thus, we performed immunostaining to
detect these factors in dystrophic muscles (Figure 6 and
Supplemental Figure S4). MMP-9 and TIMP-1 expression
was observed in both the dystrophic diaphragm and TC
muscles at the age of 3.5 months. MMP-9 was strongly
expressed in inﬁltratingmononuclear cells, which weremainly
CD11b- and CD18-positive macrophages or granulocytes
(Supplemental Figure S4), and was not detected in dMyHC-
positive muscle ﬁbers (Figure 6). TIMP-1 was expressed in
CD11b- and CD18-positive mononuclear cells and in
dMyHC-positive regenerating muscle ﬁbers. At the age of 2
years, the expression of MMP-9 and TIMP-1 was observed
only in some interstitial cells (data not shown).Discussion
We report that the serum OPN level in dystrophic dogs is
elevated and reveals a different pattern compared with serum
CK and MMP-9 levels and that this elevation pattern is related
to muscle regeneration. Recently, OPN has been considered to
be not only an inﬂammatory cytokine that functions in cellular
adhesion and chemotaxis of immune cells, including macro-
phages,34,35 but also a myogenic factor that promotes myoblast
migration, proliferation, and fusion into myotubes.11,12 Our
results suggest that serum OPN can be a new biomarker of
DMD that indicates muscle regeneration.
OPN was expressed in immune cells and a subset of regen-
erating muscle ﬁbers of the dystrophic dog muscles, and a
similar phenotype is also observed in patients with DMD.15
OPN is expressed in macrophages, ﬁbroblasts, myoblasts, and
myotubes during the muscle regeneration process after injury
by intramuscular injection of snake venom.14 The up-regulation
of OPN expression (6 to 48 hours and 3 to 14 days after venom)
is correlated with two distinct phases that consist of the in-
ﬂammatory response and muscle regeneration. These obser-
vations strongly suggest that OPN is an important mediator of
muscle regeneration in the early phase.10 We also observed a
higher percentage of OPN-positive regenerating muscle ﬁbers
for a longer period in the dystrophic diaphragm, where muscle
regeneration is very active,36 compared with analysis of
dystrophic TC muscles. Previous ﬁndings in our laboratory
revealed that regenerating muscle ﬁbers expressing slow-type
myosin heavy chain are increased after the age of 4 months
in the dystrophic dog diaphragm, whereas fast-type myosin
heavy chain is predominant in the TC muscles.31 We speculate
that OPN may be more closely related to slow-type muscle
ﬁbers than fast-type ﬁbers during muscle ﬁber maturation,
although further study is necessary.
In the present study, the serum OPN level in dystrophic
dogs was elevated and revealed a different pattern compared1310with that of serum CK, an established primary biomarker of
DMD that indicates muscle injury.4 The serum CK level in
dystrophic dogs was drastically elevated 1 hour after birth
compared with the level just before birth, conﬁrming our
previous results that initial pulmonary respiration causes
massive diaphragm injury in neonatal dystrophic dogs
(Figure 2, A and B).20 Furthermore, we found that serum
OPN was elevated in relation to muscle regeneration during
the progressive phase, but not the chronic phase, when
muscle regeneration is inactive. In mdx mice, the serum OPN
level is increased at the ages of 4 and 16 weeks.13 Active
immune cell inﬁltration and muscle regeneration are seen in
muscle tissues in these mdx mice,37,38 but whether the serum
OPN level is related to muscle regeneration has not been
veriﬁed. During the muscle regeneration process induced by
cardiotoxin injection, OPN expression was present in inﬁl-
trating immune cells and regenerating muscle ﬁbers, and
serum OPN tended to increase. These results support our idea
that serum OPN reﬂects the activity of muscle regeneration in
skeletal muscles in dystrophic dogs.
Next, we compared the serum OPN levels to levels of serum
MMP-9, an indicator of muscle inﬂammation,21e23 and its in-
hibitor TIMP-1 to further conﬁrm whether serum OPN was
indicative of muscle regeneration or inﬂammation. OPN con-
tributes to increased amounts of MMP-9 as an immunomodu-
lator,39 but the serum levels of these two factors were not
similarly elevated in the dystrophic dogs. The serum MMP-9
level in dystrophic dogs was signiﬁcantly increased 1 hour
after birth compared with the level just before birth, and the
pattern was similar to that of serum CK but not OPN. MMP-9
appears to rapidly reﬂect the inﬂammatory response, which can
be explained by the following two reasons: the latent MMP-9
form (ie, deposited in the extracellular matrix) can be quickly
converted to the active form through a proteolytic cascade,40
and MMP-9 can be immediately released from acutely inﬁl-
trating granulocytes due to storage of MMP-9 in the granules.41
In dystrophic dogs at the age of 3 months, both serumOPN and
MMP-9 levels were signiﬁcantly elevated compared with those
in WT dogs. This consistent elevation actively reﬂects a serial
change in muscle inﬂammation and regeneration. The elevation
pattern of serum TIMP-1 was similar to that of serumOPN, and
TIMP-1 expression was also observed in immune cells and
regenerating muscle ﬁbers in dystrophic muscles. Regarding
the similar aspects of OPN and TIMP-1, these two factors may
coordinately interact with each other in an MMP-independent
manner. Indeed, TIMP-1 plays roles in the processes of cell
growth, myogenesis, and ﬁbrosis in addition to inhibiting
MMP-9.25,26,42 However, serum TIMP-1 levels were not
signiﬁcantly different between dystrophic and WT dogs.
Detection of serum OPNmay be easier than detection of serum
TIMP-1 in dystrophic dogs.
An important remaining question is whether we can use
serum OPN as a novel biomarker in human DMD based on
our dog results. The serum OPN level in dystrophic dogs
was signiﬁcantly correlated with the phenotypic severity at
the onset of clinical signs, suggesting that serum OPN canajp.amjpathol.org - The American Journal of Pathology
Serum Osteopontin in Dystrophic Dogsbe related to dystrophic disease in the early phase. In a
previous study, the serum OPN levels were not signiﬁcantly
different between patients with DMD and controls, whereas
the serum MMP-9 and TIMP-1 levels were signiﬁcantly
increased.21 The limitation of their study is that they
included DMD patients with high mean ages (13.1  6.2
years; range, 2.9 to 31.2 years), and therefore, muscle
regeneration was not expected to be active in those patients’
muscles. Indeed, muscle regeneration in skeletal muscles of
patients with DMD becomes inactive around the age of 9
years.43 We propose that the serum OPN level should be
analyzed in young patients with DMD. We expect that
serum OPN in patients with DMD can be used as a surro-
gate end point in clinical trials with a muscle regeneration
inducer (eg, using granulocyte colony-stimulating factor),
which improves the dystrophic phenotypes of utrophin-
dystrophin double-knockout mice.44
Finally, the cleaved form of OPN, which is cleaved by
thrombin or MMP-3, -7, and -12, actively regulates cell
behavior and has high afﬁnity for multiple integrin subtypes in
other inﬂammatory and neoplastic disorders.6,8,9,45e48 The
ratios of thrombin-cleaved versus noncleaved OPN in rheu-
matoid arthritis are signiﬁcantly increased in plasma and sy-
novial ﬂuid compared with plasma from healthy controls.49
We attempted to distinguish cleaved and noncleaved forms
of OPN in canine serum and plasma samples. However, we
found that this distinction was difﬁcult because we performed
sandwich ELISA assay with two polyclonal anticanine OPN
antibodies against unidentiﬁed epitopes, but anticanine OPN
antibodies against the N-terminal and C-terminal halves were
not available, and separation according to molecular weight in
immunoblotting was not able to be optimized in the serum or
plasma samples because of excessive amounts of albumin,
which yielded close molecular weight to noncleaved form of
glycosylated OPN, although we excluded serum or plasma
albumin with commercially available kits. As a next step,
identiﬁcation of the cleaved and noncleaved forms of OPN in
the plasma of patients with DMD could be feasible by ELISA
with commercial antihuman OPN antibodies against the
N-terminal and C-terminal halves. Further analysis of each
form could reveal the additional properties and roles of OPN in
dystrophic disease.
In conclusion, serum OPN is a promising indicator of
muscle regeneration in dystrophic dogs and may lead to the
development of a novel biomarker for DMD. Moreover,
serum OPN is expected to be applicable as a surrogate end
point in clinical trials aimed at developing new treatments
for DMD and other muscle disorders.Acknowledgments
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